Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, focusing on how contemporary therapeutic choices in metastatic hormone-sensitive ...

One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others. A study published in Nature Communications, by a multidisciplinary team ...

One pill for obesity is already on the market, and more are on the way. But the injected drugs have key advantages.

After a routine blood test led to his diagnosis, the 70-year-old travel expert urges everyone to prioritize health exams.

A Brit has become the first patient in Europe to trial a pioneering antibody drug that ‘attaches’ to cancer cells. Brian Holmes, 70, has suffered with metastatic prostate cancer for two years and has ...

A foundational guide for stage 2 prostate cancer clarifies staging implications, localized-disease management, and trade-offs among surgery, radiation, and quality-of-life outcomes to support informed ...

A new international study has found that combining two cancer medicines may significantly slow the growth of a dangerous form of prostate cancer in some men. The research was led by scientists at ...

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and rema ...